Allergy

TREAT

(_Transdermal _Relief: _Evaluating _Allergy _Topicals for Perennial Allergic Rhinitis)

TREAT is an IRB-approved observational study to evaluate patients’ experiences and/or perceptions of prescribed transdermal allergy medications to treat seasonal and perennial allergy symptoms.

Become a Study Investigator

TREAT Study: Currently not enrolling

Continue to our other Studies:

APPLY NOW

To learn more about our TREAT study, please call our dedicated Healthcare Provider HelpDesk at

(800) 616-9403.

Principal Investigator

Thomas F. Smith, MD, FAAAAI, FACAAI, FAAP

Greater Austin Allergy, Asthma & Immunology, PLLC
Austin, TX

Clinical Professor of Internal Medicine and Pediatrics
College of Medicine, Texas A&M Health Science Center
Round Rock, TX

AffiliationsFellow of the American Academy of Allergy, Asthma, and Immunology
Fellow of the American College of Allergy, Asthma, and Immunology
Joint Council of Allergy and Immunology, Texas Allergy and Immunology Society
Member, Expert Panel for Allergy of the Texas Medical Board

Study Objective

To evaluate patient perceptions of allergic rhinitis treatment with the use of topical formulations via a patient-reported survey.

Assessment Tools

TREAT evaluates patient experiences and responses to transdermal allergy treatment based on the widely used Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ), developed to measure the functional problems (physical, emotional, social, and occupational) in patients suffering from seasonal or perennial rhinoconjuctivitis. It also evaluates based on the Quality of Life (QOL) for allergic rhinitis.

TREAT Outcomes

Our TREAT study is underway. We look forward to sharing data as soon as it is available.

TREAT Conference Highlights

MORE TREAT CONFERENCES

Become a Study Investigator

TREAT Study: Currently not enrolling

Continue to our other Studies:

APPLY NOW

To learn more about our TREAT study, please call our dedicated Healthcare Provider HelpDesk at

(800) 616-9403.

made with by fahrenheit